



Iberoamerican Journal of Medicine

ISSN: 2695-5075

ISSN-L: 2695-5075

iberoamericanjm@gmail.com

Hospital San Pedro

España

Castro, Maximiliano Gabriel; Ubierno, Lucía; Vicino,
Macarena; Cuevas, Gisel; Argaraña, Fernanda
Rising incidence of carbapenem resistant isolates: an Argentinian hospital's
experience. More trouble in the aftermath of the COVID-19 pandemic
Iberoamerican Journal of Medicine, vol. 4, núm. 2, 2022, pp. 92-99
Hospital San Pedro
España

DOI: <https://doi.org/10.53986/ibjm.2022.0020>

Disponible en: <https://www.redalyc.org/articulo.oa?id=692072546008>

- Cómo citar el artículo
- Número completo
- Más información del artículo
- Página de la revista en [redalyc.org](https://www.redalyc.org)

[redalyc.org](https://www.redalyc.org)

Sistema de Información Científica Redalyc

Red de Revistas Científicas de América Latina y el Caribe, España y Portugal
Proyecto académico sin fines de lucro, desarrollado bajo la iniciativa de acceso
abierto



**IBEROAMERICAN
JOURNAL OF
MEDICINE**

iberoamericanjm

Journal homepage: www.iberoamjmed.com

Original article

Rising incidence of carbapenem resistant isolates: an Argentinian hospital's experience. More trouble in the aftermath of the COVID-19 pandemic

Maximiliano Gabriel Castro ^{a,*}, **Lucía Ubiergo** ^a, **Macarena Vicino** ^a, **Gisel Cuevas** ^{a,b}, **Fernanda Argaraña** ^{c,d}

^aDepartment of Internal Medicine, Dr. JB Iturraspe Hospital, Santa Fe, Argentina

^bFaculty of Medical Sciences, National University of Litoral, Santa Fe, Argentina

^cDepartment of Microbiology, Dr. JB Iturraspe Hospital, Santa Fe, Argentina

^dFaculty of Biology and Biological Sciences Sciences, National University of Litoral, Santa Fe, Argentina

ARTICLE INFO

Article history:

Received 23 February 2022

Received in revised form 27

March 2022

Accepted 12 April 2022

Keywords:

Carbapenem-resistant

Enterobacteriaceae

Antibiotic resistance

COVID-19

SARS-CoV-2

Outbreak

ABSTRACT

Introduction: During COVID-19 outbreaks, disproportionate use of antibiotics, high Intensive Care Units burden and longer in-hospital stays may have aggravated the emergency posed by carbapenem-resistant isolates. Therefore, we set out to determine whether the incidence of carbapenem-resistant isolates rose in a tertiary care center in Santa Fe, Argentina during the period with active cases of COVID-19.

Material and methods: In this retrospectively designed analytic epidemiologic study, two periods were defined: Period 1 (without active cases of COVID-19) from September 2019 to August 2020 and Period 2 (starting at the onset of the first wave of COVID-19 in this Institution) from September 2020 to June 2021. All clinically relevant microbiological samples taken during these periods in the Internal Medicine, Surgical and Intensive Care Unit wards were included. The primary analysis of interest was the differential incidence between the two periods, overall and in the Intensive Care Units wards in particular.

Results: 9,135 hospitalizations, 50,145 patient-days of analysis. 7,285 clinical samples were taken, with an overall positivity for carbapenem-resistant isolates of 12.1% (n=883). Overall carbapenem-resistant isolates incidence during Period 2 was 2.5 times higher than in Period 1 (2.52 vs 0.955/100 patient-days, p<0.001). Intensive Care Units' carbapenem-resistant isolates incidence raised from 6.78 to 8.69/100 patient-days in Period 2 (p=0.006).

Conclusions: We found alarming rates of carbapenem-resistant isolates in our center, 2.5 times higher in the period following the first wave of COVID-19. This rise was due to a higher amount of clinically relevant microbiological samples taken and to a higher carbapenem resistance among *Enterobacteria* and non-fermentative Gram-negative bacilli. To our knowledge, this is one of the few Latin-American reports on the effect of the COVID-19 pandemic on carbapenem-resistant isolates incidence.

© 2022 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

* Corresponding author.

E-mail address: mgabrielcastro@outlook.com

ISSN: 2695-5075 / © 2022 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license

(<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.53986/ibjm.2022.0020>

Incidencia creciente de aislamientos resistentes a carbapenémicos: la experiencia de un hospital argentino. Más problemas tras la pandemia de COVID-19

INFO. ARTÍCULO

Historia del artículo:

Recibido 23 Febrero 2022

Recibido en forma revisada 27

Marzo 2022

Aceptado 12 Abril 2022

Palabras clave:

Enterobacterias resistentes a carbapenémicos

Resistencia a los antibióticos

COVID-19

SARS-CoV-2

Brote

RESUMEN

Introducción: Durante los brotes de COVID-19, el uso desproporcionado de antibióticos, la alta carga de las Unidades de Cuidados Intensivos y las estancias hospitalarias más prolongadas pueden haber agravado la emergencia planteada por los aislados resistentes a carbapenémicos. Por lo tanto, nos propusimos determinar si la incidencia de aislamientos resistentes a carbapenémicos aumentó en un centro de tercer nivel de atención en Santa Fe, Argentina, durante el período con casos activos de COVID-19.

Material y métodos: En este estudio epidemiológico analítico de diseño retrospectivo se definieron dos periodos: Período 1 (sin casos activos de COVID-19) de septiembre de 2019 a agosto de 2020, y Período 2 (a partir del inicio de la primera ola de COVID-19. en esta Institución) desde septiembre de 2020 hasta junio de 2021. Se incluyeron todas las muestras microbiológicas clínicamente relevantes tomadas durante estos períodos en las salas de Medicina Interna, Quirúrgica y Unidad de Cuidados Intensivos. El principal análisis de interés fue la incidencia diferencial entre los dos períodos, en general y en las salas de las Unidades de Cuidados Intensivos en particular.

Resultados: 9.135 hospitalizaciones, 50.145 pacientes-día de análisis. Se tomaron 7.285 muestras clínicas, con una positividad global para aislados resistentes a carbapenémicos del 12,1% (n=883). La incidencia general de aislamientos resistentes a carbapenémicos durante el Período 2 fue 2,5 veces mayor que en el Período 1 (2,52 frente a 0,955/100 pacientes-día, $p<0,001$). La incidencia de aislamientos resistentes a carbapenémicos en Unidades de Cuidados Intensivos aumentó de 6,78 a 8,69/100 pacientes-día en el Período 2 ($p=0,006$).

Conclusiones: Encontramos tasas alarmantes de aislamientos resistentes a carbapenémicos en nuestro centro, 2,5 veces mayores en el período posterior a la primera ola de COVID-19. Este aumento se debió a una mayor cantidad de muestras microbiológicas clínicamente relevantes tomadas ya una mayor resistencia a carbapenémicos entre *Enterobacterias* y bacilos Gram-negativos no fermentadores. Hasta donde sabemos, este es uno de los pocos informes latinoamericanos sobre el efecto de la pandemia de COVID-19 en la incidencia de aislados resistentes a carbapenem.

© 2022 Los Autores. Publicado por Iberoamerican Journal of Medicine. Éste es un artículo en acceso abierto bajo licencia CC BY (<http://creativecommons.org/licenses/by/4.0/>).

HOW TO CITE THIS ARTICLE: Castro MG, Ubiergo L, Vicino M, Cuevas G, Argaraña F. Rising incidence of carbapenem resistant isolates: an Argentinian hospital's experience. More trouble in the aftermath of the COVID-19 pandemic. Iberoam J Med. 2022;4(2):92-99. doi: 10.53986/ibjm.2022.0020.

1. INTRODUCTION

Regarding the Coronavirus disease 2019 (COVID-19) pandemic, now that widespread vaccination has helped to control outbreaks around the world, we have been left to deal with the aftermath on many fronts. As for infectious diseases, we are yet to assess what landscape of antibiotic resistance we will have to face.

Contrary to seasonal, as well as pandemic influenza, which frequently presented with concomitant bacterial lung infections, available studies regarding COVID-19 have shown an incidence of bacterial co-infections of between 7-8% in hospitalized patients, which may escalate up to 16% in those critically-ill [1]. However, estimates of antibiotic administration reached approximately 70% [2], with

predominance of broad-spectrum antibiotics.

From the nationwide perspective of different countries around the globe, even in places with a marked decline in overall antibiotic consumption due to reductions in outpatient antibiotic administration, the amount of prescribed doses of antibiotics per hospital admission increased during the COVID-19 pandemic [3]. This may not only be in line with early empiric antibiotic treatment but also with the fact that COVID-19 patients have been described to have longer Intensive Care Unit (ICU) stays, with longer need for mechanical ventilation and more frequent tracheostomies [4], in close relationship to a higher rate of hospital-acquired infections [5].

Greater use of antibiotics in hospital settings, which are the niche for multidrug-resistance development, may add to the already complex situation regarding carbapenem resistance,

which appears to be rising [6], and which is mainly associated with antibiotic misuse.

On top of everything, the need for new personnel and the redistribution of the existing staff to cope with the pandemic is necessary. In addition, it is required the spread of certain practices such as the use of double pair of gloves -out of fear of contagion at the start of the pandemic- and the lack of resources for Antibiotic Stewardship Programs may have pressured antibiotic resistance. However, there is an increasing albeit scarce evidence available on this matter, especially in Latin America and the Caribbean.

We therefore set out to determine whether the incidence of carbapenem-resistant isolates (CRI) from clinically relevant microbiological samples rose during the period with active cases of COVID-19 in a tertiary-care center from Santa Fe, Argentina.

2. MATERIAL AND METHODS

This was an analytic epidemiologic study retrospectively designed in order to assess the incidence of CRI in microbiological samples of clinical relevance, in an Argentinian hospital during the COVID-19 pandemic, compared to a previous period.

This study was conducted in Dr. JB Iturraspe Hospital, Santa Fe (Argentina), which is one of the two major hospitals in the province's capital city, which are of reference to the whole north-center region of said province. The authors acted in accordance to the Helsinki Declaration and the Hospital's Teaching Committee and the Province's Bioethical Committee approved the study.

Two periods were defined: P1 (without active cases of COVID-19) from September 2019 to August 2020 and P2 (starting at the onset of the first wave of COVID-19 in this Institution) from September 2020 to June 2021.

Inclusion criteria: All clinically relevant microbiological samples taken during the study periods from adult patients in the Internal Medicine, Surgical and ICU wards were included. We defined clinically relevant microbiological samples as all samples collected by decision of the treating physicians for diagnostic purposes, with the exclusion of rectal swabs as well as all surveillance samples.

The presence of bacterial growth from blood culture aerobic bottles was ascertained through the Bact/ALERT 3D System (bioMérieux, Argentina). A blood culture set, for the purpose of this report is considered to be composed of one to three blood culture aerobic bottles taken at once. Blood samples taken from catheter lumens were treated similarly. Various fluids cultures (VFC) were composed of clinical samples extracted from synovial, ascitic, pleural or

pericardial fluid, while various materials cultures (VMC) were composed of clinical samples extracted from abscesses and diverse tissues.

Bacterial identification and susceptibility testing were performed with the automated system Vitek 2C (bioMérieux, Argentina). Resistance to carbapenems was defined according to cutoff values on CLSI M100-ED32:2022 Performance Standards for Antimicrobial Susceptibility Testing: CIM for imipenem/meropenem ≥ 4 $\mu\text{g/ml}$ [7, 8].

The primary aim of this study was to determine whether there was a higher incidence of CRI during P2, if compared to P1. Secondary aims were to determine: whether there was a higher incidence of CRI during P2 in ICU wards in particular; whether the positivity for *Enterobacterales* and NFGNB was higher in P2 and whether such isolates bore higher rates of carbapenem resistance.

Incidence density was calculated by dividing the number of CRI during each period by the count of patient-days during that same period, multiplied by a hundred. Patient-day was the sum of the in-hospital length of stay -measured in days- of individual patients during a period. 95% confidence intervals were calculated using the OpenEpi software.

Comparisons between incidences were performed using Fisher's exact test. The limit for statistical significance was a two-sided $p < 0.05$.

Statistical analyses were performed with both OpenEpi and SPSS Statistics v27.0. Graphs were generated using Microsoft Excel 365.

3. RESULTS

Taken together, both periods included 9,135 hospitalizations, and 50,145 patient-days of analysis. P1 represented 62.8% of hospitalizations but only 48.7% of patient-days, with a monthly decline in hospitalizations in P2 (340 vs 478). The surgical ward, which had the leading number of admissions (60.0%), showed a decline in monthly admissions in P2 (158 vs 325). While the Internal Medicine ward showed no significant change in admissions between the periods, three new ICU wards had to be opened (totalling 6 UCI wards) during the P2 due to an increase in monthly admissions (72.6 vs 40.0). ICU mortality rose from 31.7% to 43.3%, and so did mean in-hospital stay, from 4.9 to 8.7 days. Moreover, these estimates may be biased downwards due to an increase in referral to other centers in P2 from 3.76% to 21.8%, since due to scarcity of beds in ICU wards; patients mainly remained in this center during the COVID-19 isolation period.




Figure 1: Comparison of incidences of carbapenem-resistant isolates between periods in the Intensive Care Unit wards and overall. Incidences are shown as CRI per 100 patients-day (blue bars) with 95% CI (black lines).

CRI: Carbapenem-resistant isolates; P1: Period 1; P2: Period 2; ICU: Intensive Care Unit.

7,285 clinical samples were taken, the majority of which were blood culture sets (n=3,238, with a monthly estimate that raised 1.7 times in P2 at the expense of ICU wards). In second place, clinical samples from respiratory samples and catheter tips also increased by 1.9 and 2.18 times, respectively (Table 1). 1,588 *Enterobacterales* and 604 non-fermentative Gram-negative bacilli (NFGNB) were isolated. Monthly incidence rose in P2 overall and regarding *Enterobacterales* in particular (5.67 vs 3.00/100 patients-day, $p<0,001$ and 4.08 vs 2.20/100 patients-day, $p<0,001$, respectively). 62.8% of these isolates came from patients in the UCI ward.

883 CRI were isolated (80.0% from the ICU wards) from 359 patients, which barely tripled during P2 (640 vs 233). Overall CRI incidence was 1.66/100 patient-days (CI 95% 1.55-1.78). Overall CRI incidence during P2 was 2.5 times higher than in P1 (2.52 vs 0.955/100 patient-days, $p<0,001$). ICU CRI incidence raised from 6.78 to 8.69/100 patient-

days in P2 ($p=0.006$) (Figure 1).

Overall blood cultures positivity to CRI rose from 3.58% to 9.16% ($p<0,001$), urine culture positivity from 4.7% to 14.4% ($p<0,001$) and respiratory samples culture from 28.9% to 47.7% ($p<0,001$). Other changes in positivity rates are shown in Table 1.

Carbapenem resistance among *Enterobacterales* and NFGNB rose from 30.4% in P1 to 43.9% in P1 ($p<0,001$). *Enterobacterales* represented 63.3% of CRI, with predominance of *Klebsiella pneumoniae* (n=307) followed by *Proteus mirabilis* (n=129). Among non-fermentative Gram-negative bacilli, there were 157 *Acinetobacter baumannii* isolates and 156 *Pseudomonas aeruginosa* isolates (Table 2).

Each patient with at least one CRI had a mean of 2.32 isolates during the in-hospital stay, without significant differences between periods.

The temporal trends in monthly incidence of CRI are shown in Figure 2. Number of monthly isolates with broad confidence intervals did not permit month-to-month comparisons during P1, which showed frequent numerical changes in CRI incidence. A significant decline in the incidence of CRI developed at the end of P1 -parallel to a decrease in hospitalizations-, followed by a rapid and steady increase at the start of P1, which later stabilized.

4. DISCUSSION

In this study, we hypothesized that during the COVID-19 pandemic there would be an increase in carbapenem resistance incidence in our center, based on the disproportionate use of antibiotics, longer in-hospital stay and the higher ICU occupancy during this period, as well as the worldwide trend in carbapenem resistance growth.

Table 1: Number of culture samples and positivity rate for carbapenem-resistant isolates, divided by culture type and period				
Type of culture	Period 1 n (% CRI)	Period 2 n (% CRI)	Total n (% CRI)	p-value
Blood cultures	1340 sets (3.58%)	1898 sets (9.16)	3238 sets (6.86)	<0,001
Blood cultures from catheter lumen	147 sets (10.9)	216 sets (11.5)	363 sets (11.3)	NS
Catheter tip	214 (14.0)	469 (21.3)	683 (19.0)	0,024
Urine culture	443 (4.74)	504 (14.4)	947 (9.93)	<0,001
VFC	360 (3.33)	289 (3.1)	649 (3.24)	NS
VMC	203 (11.3)	197 (4.50)	400 (8.00)	0,012
Respiratory cultures	283 (28.9)	545 (47.7)	828 (41.3)	<0,001
Faecal culture	96 (1.04)	81 (0.00)	177 (0.565)	NS
OVERALL	3086 (7.55)	4199 (15.2)	7285 (12.1)	<0,001

The results are presented as number (n) and percent (%). Bold letters: Significant changes in positivity rates. CRI: Carbapenem-resistant isolates; VFC: Various fluids culture; VMC: Various materials culture. NS: Non-significant.




Figure 2: Temporal trends in monthly incidences of carbapenem-resistant isolates in Intensive Care Unit wards and overall. Monthly incidences of CRI per 100 patients-day (blue and red lines) with 95% CI (black lines). CRI: Carbapenem-resistant isolates; ICU: Intensive Care Unit.

Indeed, we found a 2.5 times increase in CRI incidence overall, at the expense of ICU patients, who not only had longer in-hospital stays but also doubled in number in P2. Moreover, each patient with at least one carbapenem resistant microorganism isolated had a mean of 2.3 isolates, which did not significantly change between periods. Therefore, the fact that a large proportion of critical patients were referred to other centers before ICU discharge may have downsized the incidence of CRI, as opposed to what may have happened had they stayed.

Patient referral may have posed an epidemiologic threat due to dispersion of multidrug-resistant microorganisms between facilities that could aggravate the fact that in Santa Fe, Argentina, resistance to imipenem in *Klebsiella sp.* is already 10 points above the national estimate. However, the effect of this phenomenon has not been studied in this context. An epidemiologic study in France previous to the pandemic showed that patient transfer between facilities sustained multidrug-resistant pathogens epidemics [9].

Carbapenem resistance among *Enterobacterales* and NFGNB rose from a baseline of 30.4% to an alarming rate of 43.9%. This showed that the rise in CRI incidence was due not only to a higher number of patients, predominantly in ICU wards where patients tend to have longer in-hospital stays and more isolates per patient -with predominance of gram-negative bacilli-, but also due to higher carbapenem

resistance among isolates. Therefore, it highlights the need for urgent Infections Control measures, reviewing what aspects during the pandemic may have influenced this rise in carbapenem resistance.

Table 2. Absolute and relative frequencies of isolated microorganisms with carbapenem resistance

Microorganism	n (%)
<i>Klebsiella pneumoniae</i>	307 (34.77)
<i>Acinetobacter baumannii</i>	157 (17.78)
<i>Pseudomonas aeruginosa</i>	157 (17.78)
<i>Proteus mirabilis</i>	129 (14.61)
<i>Serratia marcescens</i>	66 (7.47)
<i>Enterobacter cloacae complex</i>	29 (3.28)
<i>Escherichia coli</i>	8 (0.91)
<i>Pseudomonas putida</i>	7 (0.79)
<i>Morganella morganii</i>	6 (0.68)
<i>Aeromonas hydrophila</i>	5 (0.57)
<i>Proteus penneri</i>	3 (0.34)
<i>Pseudomonas fluorescens</i>	3 (0.34)
<i>Proteus vulgaris</i>	2 (0.23)
<i>Providencia stuartii</i>	2 (0.23)
<i>Aeromonas sobria</i>	1 (0.11)
<i>Chryseobacterium indologenes</i>	1 (0.11)
TOTAL	883 (100)

The most common CRI was *Klebsiella pneumoniae*, followed by *Acinetobacter baumannii*. Carbapenem-resistant *Acinetobacter baumannii*, in particular, is an

especially dangerous threat to ICU patients. This was also found in one study in Wuhan, which showed that among the 6,8% of patients with secondary bacterial infections, *Acinetobacter baumannii* represented 35.8% and *Klebsiella pneumoniae* 30.8% [10].

Even in the absence of official Latin-American data on carbapenem resistance during the COVID-19 pandemic, many centers worldwide have reported a surge in CRI, albeit with heterogeneous methodologies and only a few of them with longitudinal data.

Early on in the pandemic, studies reported on episodic outbreaks of CRI, either to highlight the isolation of new strains of multidrug-resistant *Enterobacterales* and NFGNB or to describe the epidemiology of CRI in COVID-19 patients [11-21]. Despite the low number of bacterial co-infections at admission [22], the fact that the majority of the reports came for ICU settings coincided with the fact that bacterial infections were common during hospitalization, especially in critical patients. The high use of antibiotics in hospital settings [23, 24] along with high ICU occupancy with longer hospitalizations may justify such antibiotic resistance. Indeed, an analysis of data from the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) reporting on 73 countries showed that around 40% of medical institutions presented a rise in hospital-acquired infections caused by multidrug-resistant pathogens during the pandemic [24]. However, limited capacity from most countries to report on antimicrobial resistance hinders conclusions from this data, which does not provide information on mechanisms of resistance or spectrum of resistance to individual antibiotics.

These reports on outbreaks of CRI led to multiple alerts from all over the world about the link of COVID-19 with antibiotic resistance [25, 26]. This was associated with high rates of antibiotic use without cultures and disruption of surveillance for multidrug-resistant bacteria [27], among other factors. Moreover, despite higher rates of compliance to hand hygiene and higher availability of personal protective equipment, there was a surge in wrong practices such as double-gloving [24].

An Italian report from 2020 showed a surge in CRI incidence, even with a strong Infections Control program and an overall decreasing trend from previous years [28]. Another multicenter before-after cross-sectional study from Italy showed a surge in carbapenem-resistant *Acinetobacter baumannii* incidence, albeit without changes in the incidence of carbapenemase-producing *Enterobacterales* [29]. Similar to this, a New York City center showed a tendency to a greater incidence of CRI in COVID-19 patients, after a steady decline in previous years [11]. The

majority of isolates in this report were from respiratory samples, similar to what happened in our center.

A Spanish study showed that in the same period COVID-19 patients had two times the incidence of CRI if compared to control patients (1.1 vs 0.5%) [15].

Regarding Latin-American countries, one prospective cohort study from a tertiary care center in Mexico City that included 794 patients with severe COVID-19, identified 110 hospital-acquired infections in 74 patients, the majority of which (69.6%) were caused by *Enterobacterales*, however with a low prevalence of carbapenem resistance [30].

A multicenter study regarding 46 Mexican centers (40 hospital-based laboratories and 6 external laboratories from the network Red Temática de Investigación y Vigilancia de la Farmacorresistencia-INVIFAR) monitored antibiotic resistance among critical and high-priority microorganisms. They found a surge in carbapenem resistance in *Klebsiella pneumoniae* and *Escherichia coli* isolates in blood, urine and respiratory samples, *Pseudomonas aeruginosa* isolates among respiratory and urine samples and *Acinetobacter baumannii* isolates among respiratory samples [31].

Meanwhile, a Brazilian study recently found a surge in carbapenem as well as polymyxin B resistance among healthcare-associated infections in the ICU of a tertiary care hospital during the post-pandemic period [32].

In October 2021, the Panamerican Organization of Health published a document warning about the emergence and increment of carbapenemase-producing *Enterobacterales* in Latin America. There, it highlighted the first report of *Enterobacterales* co-producing KPC and NDM carbapenemases in Argentina -as well as in other countries- and a three times increment in KPC and NDM producing *Enterobacterales* in Uruguay [33].

A Brazilian study using aggregate data from 99 hospitals from Paraná that reported 11,248 device-associated infections in 234,631 patients admitted to ICU between January 2019 and December 2020 reported a significant increase in the proportion of carbapenem-resistant *Acinetobacter baumannii* isolated in 2020 (12.4% vs 7.9%). In the trend analysis, the monthly incidence density of carbapenem-resistant *Acinetobacter baumannii* per 1000 patient-days increased significantly, while carbapenem-resistant *Klebsiella pneumoniae* per 1000 patient-days showed a gradual increase during the entire observed period, but with no change in trend [34].

Several factors may have favoured the rise of CRI incidence in our, as well as other, centers. Limited resources worldwide, together with high patient burden, may have resulted in difficult decision-making, limiting the use of gloves and gowns to certain situations. Moreover, the use of

personal protective equipment created a false sense of security for the personnel tending to cohorted COVID-19 patients. This false sense of security is a particularly dangerous epidemiological threat, since it has already been shown that there is a high likelihood of carriage of carbapenem-resistant *Enterobacterales* in gowns and gloves that come in contact with carriers of CRI [35].

Even more, during the COVID-19 pandemic, contact and respiratory isolation for all patients posed a significant burden on the health personnel. A high percentage of patients in contact isolation has shown to reduce compliance to hand hygiene, among other contact precaution measures [36]. Overcrowding, under-staffing and a high patient-caregiver ratio -all common during outbreaks of COVID-19 pneumonia- have been associated with a higher risk of cross-transmission [37].

5. CONCLUSIONS

In the midst of the COVID-19 pandemic, several factors were thought to favour outbreaks of carbapenem resistance, which had already been declared a worldwide emergency. Indeed, we found alarming rates of CRI in our center, 2.5 times higher than before the first COVID-19 wave, similar to other reports worldwide.

To our knowledge, to this date this is one of the few Latin-American studies on the effect of the COVID-19 pandemic on CRI incidence, reporting on over 800 CRI among over 50,000 patient-days of analysis. Indeed, we found alarming rates of CRI in our center, 2.5 times higher than before the first COVID-19 wave, similar to other reports worldwide.

More studies are needed to understand the real trend in carbapenem resistance and whether unified efforts in infectious control measures will be able to manage these outbreaks in the aftermath of this pandemic.

6. ACKNOWLEDGEMENTS

We thank the staff of the Internal Medicine Department at Dr. J.B. Iturraspe Hospital for their active collaboration with carbapenem resistance research and the staff of the Microbiology Laboratory for granting access to the data used in this study.

7. CONFLICT OF INTERESTS

The authors declare no conflict of interest.

8. REFERENCES

- Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect*. 2020;26(12):1622-9. doi: 10.1016/j.cmi.2020.07.016.
- Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. *Clin Infect Dis*. 2021;72(10):e533-e541. doi: 10.1093/cid/ciaa1239.
- Andrews A, Budd EL, Hendrick A, Ashiru-Oredope D, Beech E, Hopkins S, et al. Surveillance of Antibacterial Usage during the COVID-19 Pandemic in England, 2020. *Antibiotics (Basel)*. 2021;10(7):841. doi: 10.3390/antibiotics10070841.
- Socolovitch RL, Fumis RRL, Tomazini BM, Pastore L, Galas FRBG, de Azevedo LCP, et al. Epidemiology, outcomes, and the use of intensive care unit resources of critically ill patients diagnosed with COVID-19 in Sao Paulo, Brazil: A cohort study. *PLoS One*. 2020;15(12):e0243269. doi: 10.1371/journal.pone.0243269.
- d'Humières C, Patrier J, Lortat-Jacob B, Tran-Dinh A, Chemali L, Maataoui N, et al. Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France. *PLoS One*. 2021;16(4):e0250728. doi: 10.1371/journal.pone.0250728.
- Ramette A, Gasser M, Nordmann P, Zbinden R, Schrenzel J, Perisa D, et al. Temporal and regional incidence of carbapenemase-producing *Enterobacterales*, Switzerland, 2013 to 2018. *Euro Surveill*. 2021;26(15):1900760. doi: 10.2807/1560-7917.ES.2021.26.15.1900760.
- Lewis II JS. *Clinical Laboratory Standards Institute (CLSI). M100 Performance standards for antimicrobial susceptibility testing*. 32nd ed. CLSI; 2022.
- Pasteran F, Lucero C, Soloaga R, Rapoport M, Corso A. Can we use imipenem and meropenem Vitek 2 MICs for detection of suspected KPC and other-carbapenemase producers among species of *Enterobacteriaceae*? *J Clin Microbiol*. 2011;49(2):697-701. doi: 10.1128/JCM.01178-10.
- Nekkab N, Crépey P, Astagneau P, Opatowski L, Temime L. Assessing the role of inter-facility patient transfer in the spread of carbapenemase-producing *Enterobacteriaceae*: the case of France between 2012 and 2015. *Sci Rep*. 2020;10(1):14910. doi: 10.1038/s41598-020-71212-6.
- Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. *Antimicrob Resist Infect Control*. 2020;9(1):153. doi: 10.1186/s13756-020-00819-1.
- Gomez-Simmonds A, Annavaiah MK, McConville TH, Dietz DE, Shoucri SM, Laracy JC, et al. Carbapenemase-producing *Enterobacterales* causing secondary infections during the COVID-19 crisis at a New York City hospital. *J Antimicrob Chemother*. 2021;76(2):380-4. doi: 10.1093/jac/dkaa466.
- Montrucchio G, Corcione S, Sales G, Curtoni A, De Rosa FG, Brazzi L. Carbapenem-resistant *Klebsiella pneumoniae* in ICU-admitted COVID-19 patients: Keep an eye on the ball. *J Glob Antimicrob Resist*. 2020;23:398-400. doi: 10.1016/j.jgar.2020.11.004.
- Arcari G, Raponi G, Sacco F, Bibbolino G, Di Lella FM, Alessandri F, et al. *Klebsiella pneumoniae* infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital. *Int J Antimicrob Agents*. 2021;57(1):106245. doi: 10.1016/j.ijantimicag.2020.106245.
- Farfour E, Lecuru M, Dortet L, Le Guen M, Cerf C, Karnycheff F, et al. Carbapenemase-producing *Enterobacterales* outbreak: Another dark side of COVID-19. *Am J Infect Control*. 2020;48(12):1533-6. doi: 10.1016/j.ajic.2020.09.015.
- Pintado V, Ruiz-Garbajosa P, Escudero-Sanchez R, Gioia F, Herrera S, Vizcarra P, et al. Carbapenemase-producing *Enterobacterales* infections in COVID-19 patients. *Infect Dis (Lond)*. 2022;54(1):36-45. doi: 10.1080/23744235.2021.1963471.
- Amarsy R, Jacquier H, Munier AL, Merimèche M, Berçot B, Mégarbane B. Outbreak of NDM-1-producing *Klebsiella pneumoniae* in the intensive care

- unit during the COVID-19 pandemic: Another nightmare. *Am J Infect Control*. 2021;49(10):1324-6. doi: 10.1016/j.ajic.2021.07.004.
17. Mullié C, Lemonnier D, Adjidé CC, Maizel J, Mismacque G, Cappe A, et al. Nosocomial outbreak of monoclonal VIM carbapenemase-producing *Enterobacter cloacae* complex in an intensive care unit during the COVID-19 pandemic: an integrated approach. *J Hosp Infect*. 2022;120:48-56. doi: 10.1016/j.jhin.2021.11.017.
18. Dumitru IM, Dumitrascu M, Vlad ND, Cernat RC, Ilie-Serban C, Hangan A, et al. Carbapenem-Resistant *Klebsiella pneumoniae* Associated with COVID-19. *Antibiotics (Basel)*. 2021;10(5):561. doi: 10.3390/antibiotics10050561.
19. Perez S, Innes GK, Walters MS, Mehr J, Arias J, Greeley R, et al. Increase in Hospital-Acquired Carbapenem-Resistant *Acinetobacter baumannii* Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(48):1827-31. doi: 10.15585/mmwr.mm6948e1.
20. Temperoni C, Caiazza L, Barchiesi F. High Prevalence of Antibiotic Resistance among Opportunistic Pathogens Isolated from Patients with COVID-19 under Mechanical Ventilation: Results of a Single-Center Study. *Antibiotics (Basel)*. 2021;10(9):1080. doi: 10.3390/antibiotics10091080.
21. Karruli A, Boccia F, Gagliardi M, Patauner F, Ursi MP, Sommese P, et al. Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience. *Microb Drug Resist*. 2021;27(9):1167-75. doi: 10.1089/mdr.2020.0489.
22. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin Infect Dis*. 2020;71(9):2459-68. doi: 10.1093/cid/ciaa530.
23. Al-Hadidi SH, Alhussain H, Abdel Hadi H, Johar A, Yassine HM, Al Thani AA, et al. The Spectrum of Antibiotic Prescribing During COVID-19 Pandemic: A Systematic Literature Review. *Microb Drug Resist*. 2021;27(12):1705-25. doi: 10.1089/mdr.2020.0619.
24. Tomczyk S, Taylor A, Brown A, de Kraker MEA, El-Saed A, Alshamrani M, et al. Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey. *J Antimicrob Chemother*. 2021;76(11):3045-58. doi: 10.1093/jac/dkab300.
25. Monnet DL, Harbarth S. Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? *Euro Surveill*. 2020;25(45):2001886. doi: 10.2807/1560-7917.ES.2020.25.45.2001886.
26. Cantón R, Gijón D, Ruiz-Garbajosa P. Antimicrobial resistance in ICUs: an update in the light of the COVID-19 pandemic. *Curr Opin Crit Care*. 2020;26(5):433-41. doi: 10.1097/MCC.0000000000000755.
27. Rodríguez-Baño J, Rossolini GM, Schultsz C, Tacconelli E, Murthy S, Ohmagari N, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. *Trans R Soc Trop Med Hyg*. 2021;115(10):1122-9. doi: 10.1093/trstmh/traab048.
28. Belvisi V, Del Borgo C, Vita S, Redaelli P, Dolce P, Pacella D, et al. Impact of SARS CoV-2 pandemic on carbapenemase-producing *Klebsiella pneumoniae* prevention and control programme: convergent or divergent action? *J Hosp Infect*. 2021;109:29-31. doi: 10.1016/j.jhin.2020.11.030.
29. Pascale R, Bussini L, Gaibani P, Bovo F, Fornaro G, Lombardo D, et al. Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study. *Infect Control Hosp Epidemiol*. 2021;1-6. doi: 10.1017/ice.2021.144.
30. Martinez-Guerra BA, Gonzalez-Lara MF, de-Leon-Civdanes NA, Tamez-Torres KM, Roman-Montes CM, Rajme-Lopez S, et al. Antimicrobial Resistance Patterns and Antibiotic Use during Hospital Conversion in the COVID-19 Pandemic. *Antibiotics (Basel)*. 2021 Feb;10(2):182. doi: 10.3390/antibiotics10020182.
31. López-Jácome LE, Fernández-Rodríguez D, Franco-Cendejas R, Camacho-Ortiz A, Morfin-Otero MDR, Rodríguez-Noriega E, et al. Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network. *Microb Drug Resist*. 2022;28(3):338-45. doi: 10.1089/mdr.2021.0231.
32. Gaspar GG, Ferreira LR, Feliciano CS, Campos Júnior CP, Molina FMR, Vendruscolo ACS, et al. Pre- and post-COVID-19 evaluation of antimicrobial susceptibility for healthcare-associated infections in the intensive care unit of a tertiary hospital. *Rev Soc Bras Med Trop*. 2021;54:e00902021. doi: 10.1590/0037-8682-0090-2021.
33. Pan American Health Organization (PAHO). Epidemiological Alert: Emergence and increase of new combinations of carbapenemases in *Enterobacteriales* in Latin America and the Caribbean - 22 October 2021. Available from: <https://www.paho.org/en/documents/epidemiological-alert-emergence-and-increase-new-combinations-carbapenemases> (accessed January 2022).
34. de Carvalho Hessel Dias VM, Tuon F, de Jesus Capelo P, Telles JP, Fortaleza CMCB, Pellegrino Baena C. Trend analysis of carbapenem-resistant Gram-negative bacteria and antimicrobial consumption in the post-COVID-19 era: an extra challenge for healthcare institutions. *J Hosp Infect*. 2022;120:43-7. doi: 10.1016/j.jhin.2021.11.011.
35. O'Hara LM, Nguyen MH, Calfee DP, Miller LG, Pineles L, Magder LS, et al. Risk factors for transmission of carbapenem-resistant *Enterobacteriales* to healthcare personnel gloves and gowns in the USA. *J Hosp Infect*. 2021;109:58-64. doi: 10.1016/j.jhin.2020.12.012.
36. Dhar S, Marchaim D, Tansek R, Chopra T, Yousuf A, Bhargava A, et al. Contact precautions: more is not necessarily better. *Infect Control Hosp Epidemiol*. 2014;35(3):213-21. doi: 10.1086/675294.
37. Legeay C, Thépot-Seegers V, Pailhoriès H, Hilliquin D, Zahar JR. Is cohorting the only solution to control carbapenemase-producing *Enterobacteriaceae* outbreaks? A single-centre experience. *J Hosp Infect*. 2018;99(4):390-5. doi: 10.1016/j.jhin.2018.02.003.